Dan Holland

Dan’s life sciences experience includes advising:

• Oxford Biomedica in relation to a number of agreements relating to the manufacture of AZD1222, the Covid-19 vaccine candidate developed by the University of Oxford and commercialised and distributed by AstraZeneca.
• Oxford Biomedica in relation to its Licence and Clinical Supply Agreement with Juno Therapeutics, part of Bristol Myers Squibb.
• Gilead Sciences Europe in relation to a number of outsourcing agreements for core business services outside the US.
• Incyte Corporation in relation to a number of clinical and commercial supply arrangements with partners in Europe and China.
• UCB in relation to manufacturing, services agreements, research collaboration agreements, material transfer agreements, CRO agreements and facilitated management arrangements.
• Brammer Bio (now part of ThermoFisher Scientific) in relation to a number of clinical and commercial supply agreements for the manufacture and supply of viral vectors.
• BTG Plc relating to the drafting of a template distribution agreement.

‘Dan Holland provides excellent strategic advice as well as on the law. A real gentleman to deal with who is extremely responsive.

Expertise